7月7日，Twist Bioscience盘中下跌5.38%，报91.34美元/股，成交额5760.57万美元。该股早盘一度冲高至104.25美元，随后大幅回落。
消息面上，投行Evercore ISI于7月6日将Twist Bioscience评级从"跑赢大盘"下调至"与大市持平"，虽同步将目标价从66美元上调至102美元，但评级下调信号明确。股价早盘冲高超过102美元目标价后缺乏上方支撑，触发获利了结。此外，公司此前已提交最高2亿美元普通股的货架注册声明，潜在稀释压力亦对股价构成压制。目前FactSet汇总分析师平均目标价为87.56美元，当前股价仍高于该均值。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.